Inflammatory Bowel Diseases (IBD)

Latest News

Dual Biologic Therapy in Crohn’s Disease: A New Treatment Paradigm?

By

Andy Kistler, MD, PharmD

There is significant interest in optimizing medical treatments of Crohn’s disease (CD) in hopes of preventing complications and the need for surgery.

Volatile Organic Compounds in the Stool: Markers of Inflammatory Bowel Disease

By

Jessica Nye, PhD

Measurement of fecal volatile organic compounds (VOC) was effective in identifying inflammatory bowel disease (IBD) biomarkers, but not for monitoring disease activity.

Associations Between Gastrointestinal Infection and New-Onset IBD

By

Dibash Kumar Das, PhD

Certain enteric pathogens are associated with higher risk of incident inflammatory bowel disease, while others are could be protective.

Filgotinib Associated With Clinical Remission in Ulcerative Colitis Study

By

Brian Park, PharmD

At week 10, filgotinib 200mg met the primary end point with a significantly higher proportion of patients achieving clinical remission compared with placebo.

Corticosteroids for IBD May Up Risk for Severe COVID-19

For patients with inflammatory bowel disease and COVID-19, risk factors for severe disease include increasing age, comorbidities, and systemic corticosteroids.

New Guidance for Commencing IBD Treatment During the COVID-19 Pandemic

By

Jessica Nye, PhD

Patients with IBD should not alter their treatment during the COVID-19 pandemic; however, starting a new treatment regimen should be avoided.

Risk for Colorectal Cancer Relatively Low in Patients with Ulcerative Colitis

By

Emily Pond

The total lifetime risk for colorectal cancer (CRC) in patients with ulcerative colitis (UC) was comparable to that observed in the general population.

Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease

By

Vicki Moore, PhD

Investigators aimed to characterize HLH in patients with moderate-to-severe inflammatory bowel disease.

Long-Term Outcomes in Patients with Acute Severe Ulcerative Colitis Responding to IVS

By

Emily Pond

Patients with acute severe ulcerative colitis (ASUC) who responded to intravenous steroids (IVS) had a low rate of colectomy over 5 years of follow-up.

Infliximab Clearance Associated with Colectomy Requirement in Patients with Acute Severe Ulcerative Colitis

By

Dibash Kumar Das, PhD

Baseline infliximab clearance is a strong predictive factor for colectomy in hospitalized patients with acute severe UC receiving salvage therapy.

Infliximab Trough Levels Correlated with Remission in Luminal Crohn’s Disease

By

Jessica Nye, PhD

Higher infliximab trough levels were associated with clinical and endoscopic remission in patients with Crohn disease (CD), according to a substudy.

Changes to Normal Gastrointestinal Care During the COVID-19 Pandemic

By

Jessica Nye, PhD

The COVID-19 pandemic has caused physicians in the New York area to reevaluate how they care for patients with gastrointestinal (GI) diseases.

Good Prognosis for Patients with Inflammatory Bowel Disease and COVID-19

By

Jessica Nye, PhD

Patients with inflammatory bowel disease (IBD) who tested positive for SARS-CoV-2 had a good overall prognosis, despite IBD maintenance treatment.

Are Patients with Inflammatory Bowel Diseases More Susceptible to COVID-19?

By

Kwamesha Joseph

Inflammatory bowel diseases are known to be associated with changes in the body’s defense.

Texture Analysis may Distinguish Between Types of Abnormal Computed Tomography Scans

By

Jessica Nye, PhD

Texture analysis of CT scan images may provide useful quantitative information to aid in differentiating between several types of gastrointestinal lesions.

Ustekinumab Treatment of Ulcerative Colitis May Lead to Steroid-Free Remission

By

Jessica Nye, PhD

Ustekinumab treatment of moderate-to-severe ulcerative colitis (UC) was effective for some patients, according to recent research.

Adalimumab Effective in Managing IBD Symptoms in Patients with COVID-19

By

Dibash Kumar Das, PhD

Adalimumab, an anti-Tumor Necrosis Factor alpha (TNFα) antibody, may be effective in managing inflammatory bowel disease symptoms in patients with COVID-19.

Ulcerative Colitis and Fecal Transplantation: Where are We Now?

By

Andy Kistler, MD, PharmD

It is thought that dysregulation of the gut microbiome could cause increased production of pro-inflammatory toxins that can predispose patients to the development of UC.

Link Between Vedolizumab Treatment And Articular Manifestations Unclear

By

Jessica Nye, PhD

It was unclear whether treatment of inflammatory bowel disease with vedolizumab causes articular manifestations in some patients.

Segmental Histologic Normalization Does Not Improve Ulcerative Colitis Outcomes

By

Jessica Nye, PhD

Segmental histologic normalization did not improve clinical outcomes of ulcerative colitis.